Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H13Cl2NO4 |
Molecular Weight | 354.185 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC(Cl)C(=O)N1CCCC2=CC(OC(=O)C3=CC=CO3)=CC=C12
InChI
InChIKey=SBJGFIXQRZOVTO-UHFFFAOYSA-N
InChI=1S/C16H13Cl2NO4/c17-14(18)15(20)19-7-1-3-10-9-11(5-6-12(10)19)23-16(21)13-4-2-8-22-13/h2,4-6,8-9,14H,1,3,7H2
Molecular Formula | C16H13Cl2NO4 |
Molecular Weight | 354.185 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Quinafimide is an investigational compound that has been used in trials for the treatment of Amoebiasis and Helminthiasis. This phase 4 trial combined Quinfamide with the approved compound Mebendazole. The details of the mechanism of action are not known, but the overall effect is intraluminal immobilization of the Entamoeba.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02385058
In phase 4 clinical trial for the treatment of intestinal helminthiasis and amebiasis, Quinfamide (200 mg) was given orally in combination with oral Mebendazole (600 mg).
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:01:50 UTC 2023
by
admin
on
Fri Dec 15 16:01:50 UTC 2023
|
Record UNII |
O1ZB1046R1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C277
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C72156
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | |||
|
SUB10215MIG
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | |||
|
2344
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | |||
|
4484
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | |||
|
DB12780
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | |||
|
263-478-1
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | |||
|
71743
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | |||
|
CHEMBL2107014
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | |||
|
100000080278
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | |||
|
m9443
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | Merck Index | ||
|
C026546
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | |||
|
35216
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | RxNorm | ||
|
DTXSID90211320
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | |||
|
Quinfamide
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | |||
|
O1ZB1046R1
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY | |||
|
62265-68-3
Created by
admin on Fri Dec 15 16:01:50 UTC 2023 , Edited by admin on Fri Dec 15 16:01:50 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |